<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828711</url>
  </required_header>
  <id_info>
    <org_study_id>Miso-Obs-204</org_study_id>
    <nct_id>NCT00828711</nct_id>
  </id_info>
  <brief_title>Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Dose-Ranging, Phase II Study to Assess the Efficacy and Safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert for Women Requiring Cervical Ripening and Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg
      Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical
      ripening and induction of labor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Women Delivering Vaginally</measure>
    <time_frame>Interval from study drug administration to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Vaginal Delivery</measure>
    <time_frame>Interval from study drug administration to delivery (average 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>From study drug administration to hospital discharge (approximately 48 - 72 hours)</time_frame>
    <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug. These assessments were deemed as accurate and appropriate for the reporting of all serious and non serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Cesarean Delivery</measure>
    <time_frame>Interval from study drug administration to cesarean delivery (average 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical Ripening Using Composite Measure of Success</measure>
    <time_frame>12 hours after insertion of drug</time_frame>
    <description>Cervical ripening success was defined by achievement of one or more of the following by 12 hours after study drug administration:
Increase from baseline in modified Bishop score ≥3; or
Achievement of modified Bishop score of ≥6; or
Vaginal delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Oxytocin</measure>
    <time_frame>At least 30 minutes after study drug removal</time_frame>
    <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal is accurate and appropriate for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax), Maximum Plasma Concentration (Cmax), Area Under the Curve (AUC) and Terminal Half Life of Misoprostol Acid.</measure>
    <time_frame>From study drug insertion up to 2 hours post study drug removal</time_frame>
    <description>The timepoints over which the pharmacokinetic measurements were assessed, and deemed as accurate and appropriate, were as follows: 0 hours (baseline), 2, 4, 6, 8, 10 and 14 hours after insertion of the study drug, immediately prior to removal of the study drug and 0.5, 1 and 2 hours after removal of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Active Labor</measure>
    <time_frame>Interval from study drug administration to active labor (average 12 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Cervical Ripening</condition>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>MVI 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVI 100 mcg vaginal insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVI 150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVI 150 mcg vaginal insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVI 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVI 200 mcg vaginal insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVI 100</intervention_name>
    <description>Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
    <arm_group_label>MVI 100</arm_group_label>
    <other_name>Misopess (TM)</other_name>
    <other_name>Misodel (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVI 150</intervention_name>
    <description>Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
    <arm_group_label>MVI 150</arm_group_label>
    <other_name>Misopess (TM)</other_name>
    <other_name>Misodel (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVI 200</intervention_name>
    <description>Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
    <arm_group_label>MVI 200</arm_group_label>
    <other_name>Misopess (TM)</other_name>
    <other_name>Misodel (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent;

          -  Pregnant women at ≥ 36 weeks 0 days inclusive gestation;

          -  Women aged 18 years or older;

          -  Candidate for pharmacologic induction of labor;

          -  Single, live vertex fetus;

          -  Baseline modified Bishop score ≤ 4;

          -  Parity ≤ 3 (parity is defined as one or more births live or dead after 24 weeks
             gestation);

          -  Body Mass Index (BMI) ≤ 50 at the time of entry to the study.

        Exclusion Criteria:

          -  Nulliparous women participating in the pharmacokinetic (PK) arm of the study: women
             with hemoglobin level &lt; 11.0 grams per deciliter (g/dL) (confirmed within one week of
             study drug insertion);

          -  Women in active labor;

          -  Presence of uterine or cervical scar or uterine abnormality e.g., bicornate uterus.
             Biopsies, including cone biopsy of the cervix, are permitted;

          -  Administration of oxytocin or any cervical ripening or labor inducing agents
             (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment.
             Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or
             gestational hypertension;

          -  Severe pre-eclampsia marked by Hemolytic anemia, Elevated Liver enzymes, Low Platelet
             count (HELLP) syndrome, other end-organ affliction or Central Nervous System (CNS)
             findings other than mild headache;

          -  Fetal malpresentation;

          -  Diagnosed fetal abnormalities;

          -  Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate
             pattern or meconium staining);

          -  Ruptured membranes ≥ 48 hours prior to the start of treatment;

          -  Suspected chorioamnionitis;

          -  Fever (oral or aural temperature &gt; 37.5˚C);

          -  Any condition in which vaginal delivery is contraindicated e.g., placenta previa or
             any unexplained genital bleeding at any time after 24 weeks during this pregnancy;

          -  Known or suspected allergy to misoprostol, other prostaglandins or any of the
             excipients;

          -  Any condition urgently requiring delivery;

          -  Unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuscon Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Medical Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennesse Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <disposition_first_submitted>March 14, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 14, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 15, 2012</disposition_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Misoprostol vaginal insert</keyword>
  <keyword>Induction of labor</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Rate of cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pregnant women who required to be induced were recruited at 11 sites in the US</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MVI 100</title>
          <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="P2">
          <title>MVI 150</title>
          <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="P3">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVI 100</title>
          <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="B2">
          <title>MVI 150</title>
          <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="B3">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="373"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="6.24"/>
                    <measurement group_id="B2" value="25.8" spread="5.92"/>
                    <measurement group_id="B3" value="25.5" spread="5.93"/>
                    <measurement group_id="B4" value="25.8" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Women Delivering Vaginally</title>
        <time_frame>Interval from study drug administration to 24 hours</time_frame>
        <population>Analysis based on Modified Intention-to-Treat (MITT) population who delivered vaginally. Percentage of subjects who delivered vaginally is presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Women Delivering Vaginally</title>
          <population>Analysis based on Modified Intention-to-Treat (MITT) population who delivered vaginally. Percentage of subjects who delivered vaginally is presented.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.75" lower_limit="52.24" upper_limit="74.21"/>
                    <measurement group_id="O2" value="66.67" lower_limit="55.75" upper_limit="76.42"/>
                    <measurement group_id="O3" value="76.00" lower_limit="66.43" upper_limit="83.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary objective of this study is to compare the efficacy of MVI 100 and MVI 200 based on the proportion of vaginal deliveries within 24 hours. A minimum sample size of approximately 120 subjects per arm would provide 84 subjects per arm with vaginal delivery, which would ensure &gt;80% power (with two-sided alpha of 5%) to detect a 20% improvement in the proportion of women delivering vaginally within 24 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for site effect</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>12.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Vaginal Delivery</title>
        <time_frame>Interval from study drug administration to delivery (average 24 hours)</time_frame>
        <population>Kaplan-Meier Estimates are based on Modified Intention-to-Treat (MITT) population.Subjects who had a cesarean, discharged prior to delivery or withdrew consent during first hospitalization were censored (MVI 100: 37, MVI 150: 39, MVI 200: 31) using the longest time interval from study drug administration to cesarean or to Labor &amp; Delivery discharge</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Vaginal Delivery</title>
          <population>Kaplan-Meier Estimates are based on Modified Intention-to-Treat (MITT) population.Subjects who had a cesarean, discharged prior to delivery or withdrew consent during first hospitalization were censored (MVI 100: 37, MVI 150: 39, MVI 200: 31) using the longest time interval from study drug administration to cesarean or to Labor &amp; Delivery discharge</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1744" lower_limit="1368" upper_limit="2198"/>
                    <measurement group_id="O2" value="1535" lower_limit="1292" upper_limit="2063"/>
                    <measurement group_id="O3" value="1181" lower_limit="1035" upper_limit="1443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Subjects who underwent a cesarean delivery during the first hospitalization were censored using the longest time interval from study drug administration to cesarean delivery during the first hospitalization, independent of treatment group. Subjects who, in their first hospitalization, were discharged prior to delivery or withdrew consent prior to delivery were censored using the longest time interval from study drug administration to labor and delivery discharge, independent of treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Log Rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-563</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Adverse Events</title>
        <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug. These assessments were deemed as accurate and appropriate for the reporting of all serious and non serious adverse events.</description>
        <time_frame>From study drug administration to hospital discharge (approximately 48 - 72 hours)</time_frame>
        <population>The percentage of subjects with adverse events are presented for the Intrapartum (before delivery), postpartum (maternal) and neonatal periods.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adverse Events</title>
          <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug. These assessments were deemed as accurate and appropriate for the reporting of all serious and non serious adverse events.</description>
          <population>The percentage of subjects with adverse events are presented for the Intrapartum (before delivery), postpartum (maternal) and neonatal periods.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with Intrapartum Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Maternal Postpartum Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Neonatal Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Cesarean Delivery</title>
        <time_frame>Interval from study drug administration to cesarean delivery (average 24 hours)</time_frame>
        <population>Percentage of subjects who had a cesarean delivery during the first hospitalization (safety population) is presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Cesarean Delivery</title>
          <population>Percentage of subjects who had a cesarean delivery during the first hospitalization (safety population) is presented.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.36" lower_limit="23.13" upper_limit="40.54"/>
                    <measurement group_id="O2" value="30.40" lower_limit="22.49" upper_limit="39.26"/>
                    <measurement group_id="O3" value="22.90" lower_limit="16.02" upper_limit="31.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>-8.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervical Ripening Using Composite Measure of Success</title>
        <description>Cervical ripening success was defined by achievement of one or more of the following by 12 hours after study drug administration:
Increase from baseline in modified Bishop score ≥3; or
Achievement of modified Bishop score of ≥6; or
Vaginal delivery.</description>
        <time_frame>12 hours after insertion of drug</time_frame>
        <population>Percentage of subjects with cervical ripening success at 12 hours is presented (Modified Intention-to-Treat population).</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical Ripening Using Composite Measure of Success</title>
          <description>Cervical ripening success was defined by achievement of one or more of the following by 12 hours after study drug administration:
Increase from baseline in modified Bishop score ≥3; or
Achievement of modified Bishop score of ≥6; or
Vaginal delivery.</description>
          <population>Percentage of subjects with cervical ripening success at 12 hours is presented (Modified Intention-to-Treat population).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78" lower_limit="69.16" upper_limit="84.94"/>
                    <measurement group_id="O2" value="77.60" lower_limit="69.28" upper_limit="84.57"/>
                    <measurement group_id="O3" value="80.15" lower_limit="72.29" upper_limit="86.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for site effect</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Oxytocin</title>
        <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal is accurate and appropriate for this outcome measure.</description>
        <time_frame>At least 30 minutes after study drug removal</time_frame>
        <population>Percentage of subjects who required pre-delivery oxytocin is presented (Modified Intention-to-Treat population).</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Oxytocin</title>
          <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal is accurate and appropriate for this outcome measure.</description>
          <population>Percentage of subjects who required pre-delivery oxytocin is presented (Modified Intention-to-Treat population).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.94" lower_limit="61.83" upper_limit="78.96"/>
                    <measurement group_id="O2" value="60.00" lower_limit="50.86" upper_limit="68.66"/>
                    <measurement group_id="O3" value="48.85" lower_limit="40.03" upper_limit="57.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for site effect</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>-22.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Plasma Concentration (Tmax), Maximum Plasma Concentration (Cmax), Area Under the Curve (AUC) and Terminal Half Life of Misoprostol Acid.</title>
        <description>The timepoints over which the pharmacokinetic measurements were assessed, and deemed as accurate and appropriate, were as follows: 0 hours (baseline), 2, 4, 6, 8, 10 and 14 hours after insertion of the study drug, immediately prior to removal of the study drug and 0.5, 1 and 2 hours after removal of the study drug.</description>
        <time_frame>From study drug insertion up to 2 hours post study drug removal</time_frame>
        <population>The plan was to enrol 24 subjects to the pharmacokinetic (PK) arm of the study. Only 3 subjects enrolled in the PK arm; there were too few subjects and too few samples available. Due to insufficient data, no statistical analysis was possible. Only misoprostol acid levels for each blood sampling timepoint for each subject was determined.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax), Maximum Plasma Concentration (Cmax), Area Under the Curve (AUC) and Terminal Half Life of Misoprostol Acid.</title>
          <description>The timepoints over which the pharmacokinetic measurements were assessed, and deemed as accurate and appropriate, were as follows: 0 hours (baseline), 2, 4, 6, 8, 10 and 14 hours after insertion of the study drug, immediately prior to removal of the study drug and 0.5, 1 and 2 hours after removal of the study drug.</description>
          <population>The plan was to enrol 24 subjects to the pharmacokinetic (PK) arm of the study. Only 3 subjects enrolled in the PK arm; there were too few subjects and too few samples available. Due to insufficient data, no statistical analysis was possible. Only misoprostol acid levels for each blood sampling timepoint for each subject was determined.</population>
          <units>PK Parameters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only misoprostol acid levels for each blood sampling timepoint for this one subject was determined. Due to insufficient data no statistical analysis of PK parameters was possible.</measurement>
                    <measurement group_id="O2" value="NA">Only misoprostol acid levels for each blood sampling timepoint for these two subjects were determined. Due to insufficient data no statistical analysis of PK parameters was possible.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Active Labor</title>
        <time_frame>Interval from study drug administration to active labor (average 12 hours)</time_frame>
        <population>Kaplan-Meier Estimates for Time to Onset of Active Labor presented (Modified Intention-to-Treat population). Subjects who never went into active labor during the first hospitalization were censored using the longest time interval from study drug administration to delivery (Censored subjects = MVI 100: 5; MVI 150: 7; MVI 200: 8)</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 100</title>
            <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>MVI 150</title>
            <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O3">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Active Labor</title>
          <population>Kaplan-Meier Estimates for Time to Onset of Active Labor presented (Modified Intention-to-Treat population). Subjects who never went into active labor during the first hospitalization were censored using the longest time interval from study drug administration to delivery (Censored subjects = MVI 100: 5; MVI 150: 7; MVI 200: 8)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069.00" lower_limit="885.0" upper_limit="1153.0"/>
                    <measurement group_id="O2" value="775.00" lower_limit="724.0" upper_limit="977.0"/>
                    <measurement group_id="O3" value="701.00" lower_limit="550.0" upper_limit="759.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Subjects who never went into active labor during the first hospitalization were censored using the longest time interval from study drug administration to delivery during the first hospitalization, independent of treatment group. Subjects who, in their first hospitalization, were discharged prior to delivery or withdraw consent prior to delivery will be censored using the longest time interval from study drug administration to labor and delivery discharge, independent of treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Log Rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-368</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - MVI 100</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were followed until resolution or for at least 30 days after discontinuation of study drug, whichever occurred first.</time_frame>
      <desc>All adverse events occurring to the maternal-fetal unit (pre-delivery/ intrapartum), the mother (postpartum) or the neonate were recorded. Adverse events that resulted in a cesarean delivery were reported as serious adverse events as they were medically significant events that routinely prolonged the duration of hospitalization.</desc>
      <group_list>
        <group group_id="E1">
          <title>MVI 100</title>
          <description>MVI 100 mcg vaginal insert
Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="E2">
          <title>MVI 150</title>
          <description>MVI 150 mcg vaginal insert
Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="E3">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ankyloglossia congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Atrial septal defect *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dysmorphism *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Polydactyly *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Supernumerary nipple *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Syndactyly *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Congenital syphilis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Endometritis #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Herpes simplex *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medical observation *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urine cannabinoids increased +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hydrocephalus *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal labour affecting foetus +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Arrested labour +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="125"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome neonatal +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Foetal heart rate disorder +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Neonatal disorder *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Puerperal pyrexia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Small for dates baby *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Uterine cervical laceration during labour #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penis disorder *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vaginal haematoma #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vulval haematoma +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal hypoxia *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection prophylaxis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal labour affecting foetus +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Caput succedaneum *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Foetal heart rate disorder +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="96" subjects_affected="67" subjects_at_risk="118"/>
                <counts group_id="E2" events="79" subjects_affected="62" subjects_at_risk="125"/>
                <counts group_id="E3" events="87" subjects_affected="57" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Meconium in amniotic fluid +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Umbilical cord around neck *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Uterine contractions abnormal +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="118"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="125"/>
                <counts group_id="E3" events="57" subjects_affected="54" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Uterine hypertonus +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine atony #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal respiratory distress syndrome *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any abstract,presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days prior to submission for any meeting or journal.If deemed necessary by the Sponsor for protection of proprietary information prior to patent filing,the Investigator agrees to a further delay of 60 days before any presentation or publication is submitted.Publications must be in a form that does not reveal technical information that is considered confidential or proprietary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

